Don Gabriel joins United BioSource Corp.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DON GABRIEL joined the Global Clinical Development & Operations team of United BioSource Corp., a subsidiary of Express Scripts. Gabriel will direct UBC’s consultative services to pharmaceutical sponsors developing oncology therapies.

A bone marrow transplant physician, Gabriel held a long tenure at the University of North Carolina where he served as professor of medicine, associate chief of staff, assistant dean for clinical services, acting chief of medical oncology, and service chief liaison of the Division of Hematology/Oncology.

He has co-developed an optical laser-based technology used to identify and characterize suspended particles in the blood, including circulating tumor cells.

“Joining UBC gives me the opportunity to work with an organization that is using cutting edge clinical study design to search deep into the biochemistry of new molecules and help take those molecules to the next stage of development,” said Gabriel.

YOU MAY BE INTERESTED IN

The long-awaited results from the RASolute 302 trial—a phase III clinical trial evaluating daraxonrasib, a RAS inhibitor, for the treatment of patients with previously treated, metastatic pancreatic ductal adenocarcinoma—have been read out. 
At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login